FDA's Proposed Osteoporosis Definition For PTH Trials Questioned By Lilly

FDA's proposed limitations on clinical trial eligibility for parathyroid hormone osteoporosis studies are too restrictive, Lilly said in Aug. 4 comments on FDA's "Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis" draft guidance.